The Effects of Intravenous Iron on Mobility in Elderly Patients Following Hip Fracture Surgery

Summary

The primary aim of this clinical trial is to investigate the effects of intravenous iron on recovery in mobility compared to the pre-fracture level in patients with a hip fracture The main questions it aims to answer are: It is hypothesize that intravenous iron will enhance gains in mobility and hereby recovery of mobility, increase hemoglobin (Hgb), lower fatigue, have a positive effect on skeletal muscles in the weeks and months after administration. The primary objective is to compare the effect of a single dose of ferric derisomaltose (FDI) (20 mg/kg body weight) relative to placebo on patients' recovery of functional mobility, measured as the change from baseline in the New Mobility Score. Participants will: \- Receive either a single dose of intravenous FDI (20 mg/kg body weight) (and saline) or placebo (saline) at 1-5 days after surgery. This trial will be conducted at three hospitals in Denmark, involving an anticipated 210 participants.

Timeline

Start

2025-06-09

Primary completion

2027-06-01

Completion

2027-09-14

Publications

• Jones NT, Kristensen MT, Christensen R, Alva-Jorgensen JP, Berger AL, Eggertsen MA, Bang Foss N, Henriksen M, Jensen TG, Kidholm K, Lunn TH, Nielsen MS, Palm H, Petersen PB, Stampe H, Viberg B, Overgaard S, Aasbrenn M. The effects of intravenous iron on mobility in older adults following hip fracture surgery: protocol for a multicentre, parallel group, randomised controlled trial - the IronHip trial. BMJ Open. 2026 Jul 13;16(7):e121250. doi: 10.1136/bmjopen-2026-121250.

Drugs

Indications